(PDF) P1.15-03 Clinical Characteristics of Long-Term

P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.935

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

R. Álvarez Álvarez

Publisher

Elsevier BV

Related search

P2.15-25 NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.15-35 Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.15-33 Real-World Data on Prognostic Factors for Overall Survival in NSCLC Patients Treated With Bevacizumab Combination Therapy

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology

Respiratory Medicine

English

Real World Data (Rwd) at T=4 in the Netherlands

Value in Health

Occupational Health

English

P3.01-17 Long Survivors With Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data From a Western Population

OncoTargets and Therapy

English

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English